title: Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
abstract: BACKGROUND
  Restenosis rates are low in large coronary vessels >/=3.5 mm after bare-metal stent (BMS) implantation. The benefit of drug-eluting stents (DES) in large vessels is not established.
  
  
  OBJECTIVE
  We aim to assess clinical outcomes after deployment of BMS compared to DES in patients with large coronary vessels >/=3.5 mm.
  
  
  METHODS
  We analysed 672 consecutive patients undergoing percutaneous coronary interventions with >/=3.5 mm stent implantation in native coronary artery de-novo lesions from the Melbourne Interventional Group (MIG) registry. Baseline characteristics, 30-day and 12-month outcomes of patients receiving BMS were compared to DES. Multivariate analysis was performed to identify predictors of major adverse cardiac events [MACE, consisting of death, myocardial infarction (MI) and target vessel revascularisation (TVR)].
  
  
  RESULTS
  Of the 672 PCIs performed in 844 lesions, DES was implanted in 39.5% (n=333) and BMS in 60.5% (n=511) of lesions. Patients who received DES compared to BMS were older, more likely to be diabetic, had left ventricular dysfunction <45% or complex lesions. Significantly fewer patients who presented with ST-elevation MI received DES compared to BMS. There were no significant differences in 12-month mortality (0.5 vs. 2.9%, p=0.07), TVR (3.6 vs. 4.8%, p=0.54), MI (6.3 vs. 3.4%, p=0.15), stent thrombosis (0.9 vs. 1.0%, p=0.88), or MACE (9.4 vs. 9.4%, p=0.90) in patients who received DES vs. BMS. Stent length >/=20 mm was the only independent predictor of 12-month MACE (Odds Ratio 2.07, 95% CI 1.14-3.76, p=0.02).
  
  
  CONCLUSIONS
  In this registry, BMS implantation in large native coronary vessels >/=3.5 mm was associated with a low risk of MACE and repeat revascularization at 12 months that was comparable to DES.
authors.affiliation: Department of Cardiology of the Royal Melbourne Hospital, Australia.
authors.forename: Bryan P
authors.initials: BP
authors.lastname: Yan
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Ajani
authors.forename: Gishel
authors.initials: G
authors.lastname: New
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Duffy
authors.forename: Omar
authors.initials: O
authors.lastname: Farouque
authors.forename: James
authors.initials: J
authors.lastname: Shaw
authors.forename: Martin
authors.initials: M
authors.lastname: Sebastian
authors.forename: Robert
authors.initials: R
authors.lastname: Lew
authors.forename: Angela
authors.initials: A
authors.lastname: Brennan
authors.forename: Nick
authors.initials: N
authors.lastname: Andrianopoulos
authors.forename: Chris
authors.initials: C
authors.lastname: Reid
authors.forename: David J
authors.initials: DJ
authors.lastname: Clark
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology*; D003331:Coronary Vessels; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D011237:Predictive Value of Tests; D012042:Registries / Q000706:statistics & numerical data*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D008670:Metals